Ipres long 1.5; 1.5 mg, prolonged-release tablets
Indapamide
Ipres long 1.5 is a prolonged-release tablet containing 1.5 mg of indapamide.
The active substance, indapamide, acts in the kidneys, increasing sodium and chloride excretion, and to a lesser extent, potassium and magnesium, thereby increasing urine output. This reduces blood volume and blood pressure.
Ipres long 1.5 also has a vasodilating effect, which reduces peripheral vascular resistance. Long-term treatment reduces left ventricular hypertrophy in patients with hypertension.
In patients with hypertension, long-term treatment does not affect lipid and carbohydrate levels in the blood.
Ipres long 1.5 is a diuretic used to treat primary hypertension.
Do not take Ipres long 1.5 if you have:
Before starting treatment with Ipres long 1.5, discuss it with your doctor.
Sodium levels
Before starting treatment and regularly during treatment, your doctor should order a blood test to check sodium levels, as any diuretic can cause hyponatremia (low sodium levels in the blood). Initially, it may be asymptomatic, so regular monitoring of sodium levels is necessary, especially in elderly patients and those with liver cirrhosis, where monitoring should be more frequent.
Potassium levels
Taking thiazide diuretics and diuretics with similar effects is associated with an increased risk of hypokalemia (low potassium levels in the blood). Hypokalemia can cause muscle disorders. Cases of rhabdomyolysis (muscle breakdown) have been reported, mainly in association with severe hypokalemia. Potassium levels in the blood should be checked every 4-6 weeks, especially in elderly patients, malnourished patients, and those taking other medications, patients with liver cirrhosis, edema, and ascites, and patients with coronary heart disease and heart failure. In these disorders, hypokalemia increases the risk of digitalis toxicity and the risk of arrhythmias. Patients with a prolonged QT interval on the electrocardiogram are also at increased risk. Hypokalemia, like bradycardia (excessive slowing of heart rate), can predispose to severe arrhythmias, particularly the dangerous torsade de pointes type. Potassium level monitoring should be performed in the first week of treatment. After diagnosing hypokalemia, the doctor will take appropriate action.
Calcium levels
Thiazide diuretics and diuretics with similar effects can reduce calcium excretion, contributing to a slight and transient increase in its levels in the blood. Significant hypercalcemia (high calcium levels in the blood) can also be caused by unrecognized hyperparathyroidism (overactive parathyroid glands). If it is necessary to examine parathyroid function, the doctor will recommend temporary discontinuation of indapamide treatment.
You should inform your doctor if you experience a photosensitive reaction.
In athletes, the drug may give a positive result in a doping test.
Ipres long 1.5, like thiazide diuretics, is effective only in patients with normal or slightly impaired kidney function (creatinine levels below 25 mg/L).
At the beginning of diuretic treatment, a transient increase in blood urea and creatinine levels may occur. This temporary disorder does not cause any consequences in patients with normal kidney function, but it may worsen existing kidney failure.
In case of liver failure, Ipres long 1.5, like thiazide diuretics, may cause hepatic encephalopathy, especially in the case of water and electrolyte balance disorders, which can lead to hepatic coma. If symptoms of hepatic encephalopathy (disorders of consciousness leading to coma) occur, the use of these diuretics should be discontinued immediately and medical attention should be sought as soon as possible.
The drug should not be given to children.
In elderly patients, there is no need to change the dosage. However, the drug should be used with caution.
Inform your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Ipres long 1.5 should not be taken with lithium salts.
Medicines that should be used with caution with Ipres long 1.5:
Taking the drug before, during, or after a meal does not significantly affect its action.
Before taking any medicine, consult your doctor.
Ipres long 1.5 should not be used in pregnant women. If you are pregnant or plan to become pregnant, inform your doctor. Alternative treatment should be used as soon as possible.
Indapamide passes into breast milk. Women treated with indapamide should not breastfeed.
After taking Ipres long 1.5, symptoms related to decreased blood pressure (e.g., headache, dizziness, weakness, drowsiness, vision disturbances) may occur, especially at the beginning of treatment or if another antihypertensive drug is used concurrently.
In such a situation, the ability to drive and operate machines may be impaired.
In case of doubt, consult your doctor.
If you have been diagnosed with intolerance to some sugars, you should consult your doctor before taking the drug.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor.
The recommended dose is one tablet (1.5 mg of indapamide) once a day, regardless of the severity of hypertension.
Swallow the tablets whole, without chewing, with a liquid.
If you have taken more than the recommended dose of Ipres long 1.5, contact your doctor or pharmacist immediately.
Symptoms of overdose may include: water and electrolyte balance disorders (low sodium and potassium levels in the blood), nausea, vomiting, muscle cramps, weakness, dizziness, drowsiness, polyuria or oliguria. After significant overdose, respiratory disorders and hypotension may occur.
If necessary, the doctor will provide appropriate treatment.
Take the missed dose as soon as possible, unless it is almost time for the next dose. Do not take a double dose to make up for the missed dose. If in doubt, consult your doctor.
Like all medicines, Ipres long 1.5 can cause side effects, although not everybody gets them.
The following criteria have been used to assess the frequency of side effects:
Unknown:
frequency cannot be estimated from available data
The following side effects have been observed during treatment with Ipres long 1.5:
Common: papular rash, hypersensitivity reactions, low potassium levels in the blood;
Uncommon: vomiting, purpura, low sodium levels in the blood, which may cause dehydration and hypotension, impotence (inability to achieve or maintain an erection);
Rare: dizziness, fatigue, headache, paresthesia, nausea, constipation, dry mouth, low chloride levels in the blood, low magnesium levels in the blood;
Very rare: thrombocytopenia (low platelet count), leukopenia (low white blood cell count), agranulocytosis (low granulocyte count), aplastic anemia, hemolytic anemia, arrhythmias, hypotension, pancreatitis, kidney failure, liver function disorders, angioedema and (or) urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome, hypercalcemia;
Frequency unknown: fainting, prolonged QT interval on the electrocardiogram, torsade de pointes type tachycardia, possibility of developing hepatic encephalopathy in liver failure, hepatitis, possibility of exacerbating symptoms of systemic lupus erythematosus, pemphigus vulgaris, reported cases of photosensitivity, hyponatremia with hypovolemia causing dehydration and orthostatic hypotension, increased uric acid and glucose levels in the blood, increased liver enzyme activity in the blood, myopia (nearsightedness), impaired vision or eye pain due to increased pressure (possible symptoms of fluid accumulation in the vascular layer surrounding the eye — excessive fluid accumulation between the choroid and sclera — or acute angle-closure glaucoma), blurred vision, vision disturbances, muscle weakness, cramps, tenderness, or muscle pain, especially when the patient feels unwell or has a high fever, which may be caused by abnormal muscle breakdown.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in a temperature below 25°C.
Store in the original package to protect from light and moisture.
Do not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of the month.
Do not use this medicine if you notice that the tablet is damaged.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
White, round, biconvex tablets.
The pack contains 30 tablets.
Marketing authorization holder:
VEDIM Sp. z o.o.
ul. Kruczkowskiego 8
00-380 Warsaw
Tel.: +48 22 696 99 20
Manufacturer:
Orifarm Manufacturing Poland Sp. z o.o.
ul. Księstwa Łowickiego 12
99-420 Łyszkowice
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.